Chemistry: analytical and immunological testing – Cancer
Reexamination Certificate
2004-09-15
2008-12-09
Harris, Alana M. (Department: 1643)
Chemistry: analytical and immunological testing
Cancer
C436S518000, C436S536000, C436S071000, C436S813000, C435S007100, C435S007230, C424S009340
Reexamination Certificate
active
07462491
ABSTRACT:
Serum cav-1 is disclosed as a biomarker for prostate cancer that has the power to differentiate between prostate cancer and BPH patients.
REFERENCES:
patent: 4317818 (1982-03-01), Benson et al.
patent: 4376110 (1983-03-01), David et al.
patent: 4925835 (1990-05-01), Heston
patent: 5116615 (1992-05-01), Gokcen et al.
patent: 5260224 (1993-11-01), Stossel et al.
patent: 5545807 (1996-08-01), Surani et al.
patent: 5633161 (1997-05-01), Shyjan
patent: 5783182 (1998-07-01), Thompson
patent: 5834234 (1998-11-01), Gallo
patent: 7029859 (2006-04-01), Thompson
patent: 2002/0065224 (2002-05-01), Bender et al.
patent: WO 86/03226 (1986-06-01), None
patent: WO 94/04196 (1994-03-01), None
patent: WO 94/16737 (1994-08-01), None
patent: WO 94/28129 (1994-12-01), None
patent: WO 95/19369 (1995-07-01), None
patent: WO 96/30389 (1996-10-01), None
patent: WO 97/09055 (1997-03-01), None
patent: WO 97/18454 (1997-05-01), None
patent: WO 99/22773 (1999-05-01), None
Tahir, S.A., et al. Cancer Res., 61: 3882-3885, 2001.
Liu, P. et al, Nature Cell Biology, 1: 369-375, 1999.
Li, W.-P. et al. Journal of Cell Science, 114(7): 1397-1408, 2001.
Nilsson, BO, et al. Ups. J. Med. Sci. 104(3): 199-206, 1999.
Perkins, G.L. et al. American Family Physician 68(6): 1075-1082, 2003.
Gion, M. et al. Anticancer Research 16: 2279-2284, 1996.
Gretzer, M.B. et al. Urol. Clin. N. Am. 30: 677-686, 2003.
Anonymous, Proceedings of the American Association for Cancer Research, 36, 266, #1589, Mar. 1995.
Brown et al., “Antigen retrieval in cryostat tissue sections and cultured cells by treatment with sodium dodecyl sulfate (SDS),” Histochem Cell Biol., 105, 261-267, 1996.
Chen et al., “Isolation and characterization of the promoter region of human nm23-H1, a metastasis suppressor gene,” Abstract 122: 2406, 1994.
Feron et al., “Endothelial nitric oxide synthase targeting to caveolae,” The Journal of Biological Chemistry, 271:37, 22810-22814, Sep. 13, 1996.
Garver et al., “Increased expression of caveolin-1 in heterozygous Niemann-Pick type II human fibroblasts,” Biochemical and Biophysical Research Communications, 236, 189-193, 1997.
Morre et al., “Ligand-stimulated B2-adrenergic receptor internalization via the constitutive endocytic pathway into rab5-containing endosomes,” Journal of Cell Science, 108, 2983-2991, 1995.
Parton et al., “Caveolin-3 associates with developing t-tubules during muscle differentiation,” The Journal of Cell Biology, 136:1, 137-154, Jan. 13, 1997.
Parton, “Ultrastructural localization of gangliosides; GM is concentrated in caveolae,” The Journal of Histochemistry and Cytochemistry, 42:2, 155-166, 1994.
Scherer et al., “Caveolin isoforms differ in their N-terminal protein sequence and subcellular distribution,” The Journal of Biological Chemistry, 270:27, 16395-16401, Jul. 1995.
Song et al., “Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells,” The Journal of Biological Chemistry, 271:25, 15160-15165, Jun. 21, 1996.
Wu et al., “Clustering of GPI-anchored folate receptor independent of both cross-linking and association with caveolin,” The Journal of Membrane Biology, 159: 137-147, 1997.
Aihara et al., “Frequency of apoptotic bodies positively correlates with Gleason grade in prostate cancer,” Human Pathology, 25:8, 797-801, Aug. 1994.
Aihara et al., “The frequency of apoptosis correlates with the prognosis of Gleason grade 3 adenocarcinoma of the prostate,” Cancer, 75:2, 522-529, Jan. 15, 1995.
Bist et al., “Two sterol regulatory element-like sequences mediate up-regulation of caveolin gene transcription in response to low density lipoprotein free cholesterol,” Proc. Natl. Acad. Sci. USA, 94, 10693-10698, Sep. 1997.
Block et al., “Isolation of cDNAs that are differentially expressed between androgen-dependent and androgen-independent prostate carcinoma cells using differential display PCR,” Prostate, 26:4, 213-224, Apr. 1995.
Boak et al., “Regulation of lysyl oxidase expression in lung fibroblasts by transforming growth factor-B1 and prostaglandin E2,” American Journal of Respiratory Cell and Molecular Biology, 11, 751-755, 1994.
Bookstein et al., “p53 is mutated in a subset of advanced-stage prostate cancers,” Cancer, 53, 3369-3373, Jul. 19, 1993.
Carter et al., “Prediction of metastatic potential in an animal model of prostate cancer: flow cytometric quantification of cell surface charge,” The Journal of Urology, 142, 1338-1341, Nov. 1989.
Chamness et al., “The effect of androgen on nitric oxide synthase in the male reproductive tract of the rat,” Fertility and Sterility, 63:5, 1101-1107, May 1995.
Contente et al., “Expression of gene rrg is associated with reversion of NIH 3T3 transformed by LTR-c-H-ras,” Science, 249, 796-798, August. 17, 1990.
Danks, “Disorders of copper transport: menkes disease and the occipital horn syndrome,” Connective Tissue and Its Heritable Disorders, 487-505, 1993.
Donehower, “Mice deficient for p53 are developmentally normal but susceptible to sponataneous tumours,” Nature,356, 215-221, Mar. 19, 1992.
Eastham et al., “In vivo gene therapy with p53 of p21 advenovirus for prostate cancer,” Cancer Research, 55, 5151-5155, Nov. 15, 1995.
Eastham et al., “Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models,” Human Gene Therapy, 7, 515-523, Mar. 1, 1996.
Eastham et al., “Transforming growth factor-B1: comparative immunohistochemical localization in human primary and metastatic prostate cancer,” Laboratory Investigation, 73:5, 628-635, 1995.
Egawa et al., “Alterations in mRNA levels for growth-related genes after transplantation into castrated hosts in oncogene-induced clonal mouse prostate carcinoma,” Molecular Carcinogenesis, 5, 52-61, 1992.
Einstein, “Hormonal therapy for prostate cancer—when to use it,” Cancer Control, 32-36, Jan./ Feb. 1995.
Feres-Filho et al., “Pre- and post-translational regulation of lysyl oxidase by transforming factor-B1 in osteoblastic MC3T3-E1 cells,” The Journal of Biological Chemistry, 270:51, 30797-30803, Dec. 22, 1995.
Feron et al., “Endothelial nitric oxide synthase targeting to caveolae,” The Journal of Biological Chemistry, 271:37, 22810-22814, Sep. 13, 1996.
Fielding et al, “Caveolin mRNA levels are up-regulated by free cholesterol and down-regulated by oxysterols in fibroblast monolayers,” Pro. Natl. Acad. Sci. USA, 94, 3753-3758, Apr. 1997.
Fingert et al., “In vivo model for differentiation therapy of leukemia and solid tumors,” National Institutes of Health Publication, 84- 2635, Serno Symposia Publications from Rven. Press, 277-286, 1984.
Fox et al., “p53 ans c-myc expression in stage A1 prostatic adenocarcinoma: useful prognostic determinants?,” The Journal of Urology, 150, 490-494, Aug. 1993.
Garver et al., “Increased expression of caveolin-I in heterozygous Niemann-Pick type II human fibroblasts,” Biochemical and Biophysical Research Communications, 236, 189-193, 1997.
Glenney, “Tyrosine phosphorylation of a 22-kDa protein is correlated with transformation by rous sarcoma virus,” The Journal of Biological Chemistry, 264:34, 20163-20166, Dec. 5, 1989.
Goltsov et al., “A novel p53-regulated gene encoding a four transmembrane domain in mouse prostate cancer cells,” AACR Annual Meeting, Philadelphia, PA, Apr. 10-14, 1999.
Guarini et al., “Transfer of the interleukin-2 gene into human cancer cells induces specific antitumor recognition and restores the expression of CD3/T-cell receptor associated signal transduction molecules,” Blood, 89:1, 212-218, Jan. 1, 1997.
Gudas, “Retinoids, retinoid-responsive genes, cell differenti
Baylor College of Medicine
Harris Alana M.
Holleran Anne L
Vinson & Elkins LLP
LandOfFree
Methods and compositions for diagnosis and monitoring of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for diagnosis and monitoring of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for diagnosis and monitoring of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4035759